Mode
Text Size
Log in / Sign up

Herpes Zoster

Subtypes of Herpes Zoster

Herpes zoster ophthalmicus 1 Ramsay Hunt Syndrome 1 Shingles 1

9 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Herpes Zoster

65 trials tracked for Herpes Zoster: 43 in phase 3 or 4 and 28 with published results. The most-cited published study has 256 citations.

65Trials tracked
43Phase 3 & 4
0Recruiting
28With published results
Phase distribution
Phase 4 8 Phase 3 35 Phase 2 9 Phase 1 5 Other / NA 8
  1. Phase 3 Study to Evaluate Efficacy, Safety, and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A Completed · 256 cited
  2. Phase 3 Study to Assess the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine in Adults Aged 18 Years and Older With Blood Cancers Completed · 253 cited
  3. Phase 3 Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine in Adults 18 Years of Age or Older With Renal Transplant Completed · 193 cited
  4. Phase 3 Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ/su) Vaccine in Adults With Solid Tumours Receiving Chemotherapy Completed · 118 cited
  5. Phase 3 A Study to Evaluate the Safety and Efficacy of Inactivated Varicella-zoster Vaccine (VZV) as a Preventative Treatment for Herpes Zoster (HZ) and HZ-related Complications in Participants Undergoing Hematopoietic Cell Transplants (HCTs) (V212-001) Completed · 96 cited
  6. Phase 3 A Long-term Follow-up Study (ZOE-LTFU) of Two Studies 110390 (ZOSTER-006) and 113077 (ZOSTER-022) to Assess the Efficacy, Safety, and Immunogenicity Persistence of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine and Assessment of 1 or 2 Additional Doses in Two Subgroups of Older Adults Completed · 93 cited
Show 44 more trials
  1. Phase 3 Study to Evaluate Immunogenicity and Safety of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine at 9 and 10 Years After Vaccine Administration and Assessment of Re-vaccination With 2 Additional Doses at 10 Years After Initial Vaccination, in Healthy Subjects Aged 60 Years of Age(YOA) and Older Completed · 79 cited
  2. Phase 3 Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) in Adults ≥ 65 Years of Age With and Without Zostavax® Vaccination at Least 5 Years Earlier Completed · 72 cited
  3. Phase 3 Study to Evaluate Efficacy, Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults Aged 70 Years and Older Completed · 64 cited
  4. Phase 3 Study to Evaluate Efficacy, Safety and Immunogenicity of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults Aged 50 Years and Older Completed · 63 cited
  5. Phase 3 Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine GSK1437173A in Adults With a Prior Episode of Herpes Zoster Completed · 53 cited
  6. Phase 3 Safety and Immunogenicity of Different Dosing Schedules of GlaxoSmithkline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine in Adults 50 Years of Age or Older Completed · 51 cited
  7. Phase 3 Immunogenicity and Safety Study of ZOSTAVAX Administered by Intramuscular or Subcutaneous Route to Participants Aged From 50 Years Old (V211-045) Completed · 41 cited
  8. Phase 4 Efficacy, Immunogenicity and Safety Study of GSKs Recombinant Zoster Vaccine Shingrix (GSK1437173A) in Chinese Adults Aged ≥50 Years Completed · 36 cited
  9. Phase 3 A Study to Evaluate the Safety and Efficacy of Inactivated Varicella-zoster Vaccine (VZV) as a Preventative Treatment for Herpes Zoster (HZ) and HZ-related Complications in Adult Participants With Solid Tumor or Hematologic Malignancy (V212-011) Completed · 36 cited
  10. Phase 3 Safety and Immunogenicity Study of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine GSK1437173A When Administered Subcutaneously Intramuscularly in Adults Aged ≥50 Years Completed · 36 cited
  11. Phase 3 Study to Evaluate Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A When Co-administered With Pneumovax 23™ in Adults Aged 50 Years and Older Completed · 36 cited
  12. Phase 3 A Study on the Immune Response and Safety of the Shingles Vaccine and the Influenza Vaccine When Either is Given to Healthy Adults at the Same Time or Following a COVID-19 Booster Vaccine Completed · 36 cited
  13. Phase 3 A Study on the Immune Response and Safety of a Vaccine Against Herpes Zoster in Adults Aged 50 Years and Older in India Completed · 36 cited
  14. Phase 3 Safety and Immunogenicity Study of GlaxoSmithKline's Herpes Zoster Subunit Vaccine (HZ/su) When Given on a Two-dose Schedule to Adults at Least 50 Years of Age (YOA) With a Prior Episode of Herpes Zoster Completed · 36 cited
  15. Phase 3 Study to Evaluate the Impact of Reactogenicity on Quality of Life (QoL), After Administration of GlaxoSmithKline (GSK) Biologicals' Candidate Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) in Adults ≥ 50 Years of Age Completed · 34 cited
  16. Phase 3 Study to Evaluate Immunogenicity, Safety, and Tolerability of ZOSTAVAX™ Vaccine (Zoster Vaccine Live, V211) Administered Concomitantly Versus Nonconcomitantly With Quadrivalent Influenza Virus Vaccine (Inactivated) in Participants ≥50 Years of Age (V211-062) Completed · 27 cited
  17. Phase 3 Study to Assess the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) When Co-administered With GSK Biologicals' Diphtheria, Tetanus and Pertussis Vaccine (Boostrix®) in Adults Aged 50 Years and Older Completed · 26 cited
  18. Phase 3 Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With Prevenar13 in Adults Aged 50 Years and Older Completed · 19 cited
  19. Phase 4 Zostavax® at Minimum Release Specification Approaching Expiry (V211-044) Completed · 17 cited
  20. Phase 3 Consistency, Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults ≥ 50 Years of Age Completed · 11 cited
  21. Phase 4 Immunogenicity of Herpes Zoster Subunit Vaccine in Inflammatory Bowel Disease Patients Treated With Vedolizumab Completed · 2 cited
  22. Phase 3 A Study to Test GlaxoSmithKline's (GSK) Herpes Zoster (HZ) Subunit Vaccine's Long-term Immune Response in Previously Vaccinated Kidney Transplant Adults and Then to Test if 2 Additional Doses of the Vaccine Are Safe and Able to Generate an Immune Response Completed
  23. Phase 4 T Cell Responses to Varicella Zoster Virus (VZV) Vaccine SLVP020 Completed
  24. Phase 4 Placebo Controlled Evaluation of the Cell Mediated Immune Response of Cirrhotic Subjects to Zostavax™ Completed
  25. Phase 4 Persistence of Protection by Shingrix Completed
  26. Phase 4 ZOSTAVAX™ Safety Study in Subjects ≥ 60 Years of Age (V211-020) Completed
  27. Phase 4 ZOSTAVAX™ Safety and Immunogenicity in Korean Adults (V211-034) Completed
  28. Phase 3 Phase III Study of ASP2151 in Herpes Zoster Patients Completed
  29. Phase 3 Cross-vaccination Study of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK 1437173A) in Subjects Who Previously Received Placebo in ZOSTER-006 (NCT01165177) and ZOSTER-022 (NCT01165229) Studies. Completed
  30. Phase 3 A Study of an Investigational Zoster Vaccine in Subjects With a History of Varicella (Chickenpox) Given Concomitantly With Another Vaccine (V211-011) Completed
  31. Phase 3 A Study to Evaluate Safety, Tolerability, and Immunogenicity of an Investigational Zoster Vaccine In Subjects With a History of Varicella (Chickenpox)(V211-010)(COMPLETED) Completed
  32. Phase 3 Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With GSK Biologicals' Seasonal Influenza Vaccine GSK2321138A in Adults Aged 50 Years and Older Completed
  33. Phase 3 Safety and Immunogenicity of Zoster Vaccine (ZOSTAVAX™) Made With an Alternative Manufacturing Process (AMP) (V211-042 AM1) Completed
  34. Phase 3 A Study of an Investigational Zoster Vaccine, in Subjects With a History of Herpes Zoster (V211-014) Completed
  35. Phase 3 ZOSTAVAX™ Administered Concomitantly With PNEUMOVAX™ 23 (V211-012)(COMPLETED) Completed
  36. Phase 3 Safety, Tolerability, and Immunogenicity of Zoster Vaccine Live (ZOSTAVAX™) in Healthy Adults in India (V211-025) Completed
  37. Phase 3 Safety, Tolerability, and Immunogenicity of a Booster Dose of Zoster Vaccine, Live (V211-029) Completed
  38. Phase 2 Study of Long Term Immune Responses and Safety of the GSK Herpes Zoster Vaccine in Healthy Subjects Completed
  39. Phase 2 ZOSTAVAX™ in Patients on Chronic/Maintenance Corticosteroids (V211-017) (COMPLETED) Completed
  40. Phase 2 Safety & Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1437173A Completed
  41. Phase 2 Study to Evaluate GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Human Immunodeficiency Virus (HIV)-Infected Subjects Completed
  42. Phase 2 Month 30 & 42 Extension Studies of CRD-004 Primary Study Completed
  43. Phase 2 Safety and Immunogenicity of the Zoster Vaccine GSK1437173A in Elderly Subjects Completed
  44. Phase 2 Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine With Various Formulations in Adults >= 50 Years Completed

Showing the 50 most-cited and recently-updated of 65 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.

Questions about Herpes Zoster

Does having diabetes make my Herpes Zoster infection more likely to be severe?

Yes, diabetes is linked to more severe herpes zoster, including higher rates of disseminated disease and complications like postherpetic neuralgia.

Full answer →
Is the Recombinant Zoster Vaccine recommended for immunocompromised adults aged 19 and older?

Yes, the Recombinant Zoster Vaccine (RZV) is recommended for immunocompromised adults aged 19 and older by the ACIP, with high efficacy and acceptable safety.

Full answer →
Does aging increase my risk of Herpes Zoster according to recent genomic studies?

Yes, aging increases herpes zoster risk. Genomic studies show age-related decline in VZV-specific immunity and shared genetic signals linking aging, autoimmunity, and viral reactivation.

Full answer →
What is the risk of getting Herpes Zoster if I have rheumatoid arthritis?

People with rheumatoid arthritis have a significantly higher risk of getting shingles compared to the general population, with studies showing an increased risk of about 30% to nearly 60% depending on age and other factors.

Full answer →